DE602006003848D1 - Formulierung zur verzögerten Freisetzung von Valproinsäure und deren Derivate - Google Patents

Formulierung zur verzögerten Freisetzung von Valproinsäure und deren Derivate

Info

Publication number
DE602006003848D1
DE602006003848D1 DE602006003848T DE602006003848T DE602006003848D1 DE 602006003848 D1 DE602006003848 D1 DE 602006003848D1 DE 602006003848 T DE602006003848 T DE 602006003848T DE 602006003848 T DE602006003848 T DE 602006003848T DE 602006003848 D1 DE602006003848 D1 DE 602006003848D1
Authority
DE
Germany
Prior art keywords
formulation
valproic acid
derivatives
sustained release
polymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006003848T
Other languages
English (en)
Inventor
Nava Shterman
Limor Ari-Pardo
Rina Zilberman
Yonit Triger-Messer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of DE602006003848D1 publication Critical patent/DE602006003848D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
DE602006003848T 2006-01-11 2006-01-11 Formulierung zur verzögerten Freisetzung von Valproinsäure und deren Derivate Active DE602006003848D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06250124A EP1815850B1 (de) 2006-01-11 2006-01-11 Formulierung zur verzögerten Freisetzung von Valproinsäure und deren Derivate

Publications (1)

Publication Number Publication Date
DE602006003848D1 true DE602006003848D1 (de) 2009-01-08

Family

ID=36250729

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006003848T Active DE602006003848D1 (de) 2006-01-11 2006-01-11 Formulierung zur verzögerten Freisetzung von Valproinsäure und deren Derivate

Country Status (7)

Country Link
EP (1) EP1815850B1 (de)
AT (1) ATE415151T1 (de)
DE (1) DE602006003848D1 (de)
DK (1) DK1815850T3 (de)
ES (1) ES2317450T3 (de)
PL (1) PL1815850T3 (de)
PT (1) PT1815850E (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
CN114209667A (zh) * 2016-04-08 2022-03-22 赛伦诺科技有限公司 包含丙戊酸的延迟释放药物制剂和其用途
CN107811985B (zh) * 2016-09-13 2021-05-28 四川科瑞德制药股份有限公司 一种抗癫痫缓释制剂及其制备方法与用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212326A (en) 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
US4988731A (en) 1979-08-20 1991-01-29 Abbott Laboratories Sodium hydrogen divalproate oligomer
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US5185159A (en) 1983-07-20 1993-02-09 Sanofi Pharmaceutical composition based on valproic acid and a process for preparing it
US4913906B1 (en) 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
ATE68346T1 (de) * 1987-07-22 1991-11-15 Farvalsa Ag Feuchtigkeitsstabile feste valproinsaeurezubereitung und verfahren zu ihrer herstellung.
GB8724763D0 (en) 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5009897A (en) 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
US5169642A (en) 1988-06-24 1992-12-08 Abbott Laboratories Sustained-release drug dosage units
FR2643556B1 (fr) 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
EP0571973B1 (de) 1992-05-29 2000-02-02 Nikken Chemicals Co., Ltd. Tablette zur langsamen Freisetzung von Natriumvalproat
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US6528090B2 (en) 1998-12-18 2003-03-04 Abbott Laboratories Controlled release formulation of divalproex sodium
US6419953B1 (en) 1998-12-18 2002-07-16 Abbott Laboratories Controlled release formulation of divalproex sodium
AT408718B (de) * 1999-12-02 2002-02-25 Gerot Pharmazeutika Natriumvalproat-granulat mit verringerter hygroskopizität

Also Published As

Publication number Publication date
ATE415151T1 (de) 2008-12-15
EP1815850A1 (de) 2007-08-08
PL1815850T3 (pl) 2009-05-29
EP1815850B1 (de) 2008-11-26
PT1815850E (pt) 2009-01-06
ES2317450T3 (es) 2009-04-16
DK1815850T3 (da) 2009-03-16

Similar Documents

Publication Publication Date Title
CY1109307T1 (el) Χρηση αδαπαλενιου για τη θεραπεια δερματολογικων διαταραχων
CY1110812T1 (el) Παραγωγα διφαινυλοξυοξικου οξεος για τη θεραπεια αναπνευστικων διαταραχων
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
PA8622401A1 (es) Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico,procesos para su preparacion y su uso como medicamentos
CY1112831T1 (el) Παραγωγα αζαβιρηενυlαμινοβενζοιc acid σαν παραγοντες καταστολης dhodh
SE0301010D0 (sv) Novel compounds
MX2007012443A (es) Formulaciones farmaceuticas orales que comprenden acido fenofibrico y/o sus sales.
GB0514463D0 (en) Use of pinolenic acid
CY1115058T1 (el) Παραγωγα 1,2,3- τριαζολης για χρηση ως αναστολεις στεατοϋλο-coa δεσατουρασης
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
DK2151241T3 (da) Stabilt fast præparat, omfattende 4,5-epoxymorphinanderivat
ATE425961T1 (de) Salze substituierter allophansaureester und deren verwendung in arzneimitteln
CY1112702T1 (el) Βελτιωμενη φαρμακευτικη συνθεση που περιεχει εναν αντισπασμωδικο παραγοντα πυρρολιδονης και μεθοδος για την παρασκευη της
DE602006003848D1 (de) Formulierung zur verzögerten Freisetzung von Valproinsäure und deren Derivate
WO2006071564A3 (en) Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
AU2005238141A8 (en) Pentenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof
NO20082848L (no) Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre
ATE417619T1 (de) Sporopollenin enthaltende lösliche zusammensetzung und verwendung
TW200727921A (en) Formulation for prolonged release of active ingredients of medicaments
MX2012001298A (es) Acido r-7-(3-aminometil-4-metoxiimino-3-metil-pirrolidin-1-il)-1-c iclopropil-6-fluoro-4-oxo-1,4-dihidro-[1,8]naftiridin-3-carboxili co y sal de acido l-aspartico, proceso para la preparacion de los mismos y composicion farmaceutica que comprende los mismos para antimicrobiano.
RU2009132625A (ru) Способ лечения заболеваний, вызываемых вирусом герпеса
ZA200706705B (en) Phenylbenzoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic uses thereof
PL1700597T3 (pl) Kompozycja farmaceutyczna do podawania na skórę, zawierająca łącznie ubidekarenon, despantenol oraz chlorheksydynę lub jej farmakologicznie dopuszczalną sól
BRPI0607372A2 (pt) medicamento destinado à administração oral, compreendendo um inibidor da ciclooxigenase-2, e método de preparação do mesmo

Legal Events

Date Code Title Description
8364 No opposition during term of opposition